Logo do repositório
 
Publicação

Modulation of tumor environment in colorectal cancer – could gut microbiota be a key player?

2022-09Recensão Acesso aberto
Ver registo simples
dc.contributor.authorDuarte Mendes, Ana
dc.contributor.authorVicente, Rodrigo
dc.contributor.authorVitorino, Marina
dc.contributor.authorSilva, Michelle
dc.contributor.authorAlpuim Costa, Diogo
dc.contributor.institutionNOVA Medical School|Faculdade de Ciências Médicas (NMS|FCM)
dc.contributor.pblFrontiers Media
dc.date.accessioned2024-09-30T22:33:28Z
dc.date.available2024-09-30T22:33:28Z
dc.date.issued2022-09
dc.descriptionPublisher Copyright: Copyright © 2022 Duarte Mendes, Vicente, Vitorino, Silva and Alpuim Costa.
dc.description.abstractThe treatment paradigm of neoplastic diseases has dramatically shifted with the introduction of immune checkpoint inhibitors (ICI). They induce a durable response in a wide variety of solid tumors, but this response depends on the infiltration of lymphocytes capable of recognizing and killing tumor cells. The primary predictor of intrinsic immune resistance to ICIs is the absence of lymphocytes in the tumor, the so-called “cold tumors”. Colorectal cancer (CRC) remains one of the most common and challenging cancer, but it is not traditionally considered a highly immunogenic tumor. In fact, immunotherapy showed a remarkable antitumoral activity only on a small subset of CRC patients – the ones with microsatellite instability-high/deficient DNA mismatch repair (MSI-H/dMMR). Most CRCs display a molecular microsatellite stability/proficient DNA mismatch repair (MSS/pMMR) profile, so strategies to improve tumor immunogenicity are crucial. Therefore, ongoing studies investigate new approaches to convert “cold” to “hot” tumors in MSS/pMMR CRCs. In addition, it has been described that gut microbiota influences tumor development and the host immune response. Hence, the microbiota may modulate the immune response, becoming a promising biomarker to identify patients who will benefit from ICIs. Future data will help to better understand microbiota mechanisms and their role in ICI efficacy. Precision medicine in cancer treatment could involve modulation of the microbiota through different strategies to improve tumor immunogenicity. In this review, we aim to present the potential relationship between gut microbiota and the modulation of the immune system and the hypothetical implications in CRC treatment, namely ICIs.en
dc.description.versionpublishersversion
dc.description.versionpublished
dc.format.extent7229664
dc.identifier.doi10.3389/fgstr.2022.1021050
dc.identifier.issn2813-1169
dc.identifier.otherPURE: 100281198
dc.identifier.otherPURE UUID: 4c73ccd0-5ceb-4bd2-bae9-129e810bfe7d
dc.identifier.otherScopus: 85163237558
dc.identifier.urihttp://hdl.handle.net/10362/172758
dc.identifier.urlhttps://www.scopus.com/pages/publications/85163237558
dc.language.isoeng
dc.peerreviewedyes
dc.subjectcolorectal cancer
dc.subjectdysbiosis
dc.subjectimmunity
dc.subjectimmunotherapy
dc.subjectmicrobioma
dc.subjectmicrobiota
dc.subjectpharmacomicrobiomics
dc.subjectGastroenterology
dc.subjectHepatology
dc.subjectSDG 3 - Good Health and Well-being
dc.titleModulation of tumor environment in colorectal cancer – could gut microbiota be a key player?en
dc.typereview
degois.publication.titleFrontiers in Gastroenterology
degois.publication.volume1
dspace.entity.typePublication
rcaap.rightsopenAccess

Ficheiros

Principais
A mostrar 1 - 1 de 1
Miniatura
Nome:
fgstr-01-1021050.pdf
Tamanho:
6.89 MB
Formato:
Adobe Portable Document Format
Ver/Abrir

Coleções

NMS - Artigos em revista internacional com arbitragem científica